RegeneRx Biopharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. It has formulated Tß4 into three distinct product candidates in clinical development, such as RGN-259, RGN-352 and RGN-137. The company's RGN-259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. Its RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. The RGN-137 is a topical gel for dermal wounds and reduction of scar tissue. Regenerx was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.